The new models that could help the industry encourage the adoption of personalised treatments
For health systems, personalised medicines can lead to decreased use of ineffective treatments, reduced hospitalisations and other costs associated with chronic conditions, and more efficient use of healthcare resources. But there are also a number of environmental and organisational challenges that currently prevent the effective uptake of personalised medicines and potentially hinder their development. A range of stakeholders including leading payers, policymakers and healthcare professionals have called for efforts to better understand these challenges to support target goals in patient access for new therapies while also maximising their positive impact on health systems in the UK and throughout the EU.
To better understand the factors that can affect access to personalised medicines, CRA recently completed an analysis (sponsored by EFPIA/EBE) focusing on new personalised immunotherapies and assessed the extent to which they are made available in the UK, Denmark, France, the Netherlands and Poland. These countries collectively represent a broad range in terms of geography, reimbursement mechanisms, approaches to health technology assessments (HTAs), treatment infrastructure and healthcare policies.
The analysis highlights a clear need for innovative strategies to address challenges and to prioritise personalised medicines within a...